Multicentre clinical trial of antirejection pulse therapy with deoxyspergualin in kidney transplant patients.
The present randomized comparative clinical trial was carried out to confirm the efficacy of a newly developed immunosuppressive drug, 15-deoxyspergualin (DSG), and also to find its optimal dose for antirejection pulse therapy. The study included 66 patients with rejection which had occurred within 6 months after renal transplantation. They were treated with DSG at 3, 5 or 7 mg/kg/day for 5 days. The overall percentage of efficacy was 73% and the percentage of efficacy was the highest in the 3-mg/kg group (82%). The incidence of adverse reaction tended to be dose-dependent. From these results, the optimal dose of DSG was judged to be 3-5 mg/kg/day for antirejection pulse therapy, and at doses in this range the percent efficacy could be expected to be 80% or more.
Amemiya
H
H
Department of Surgical Research, National Cardiovascular Centre, Research Institute, Suita, Japan.
Suzuki
S
S
Ota
K
K
Takahashi
K
K
Sonoda
T
T
Ishibashi
M
M
Omoto
R
R
Koyama
F
F
Orita
K
K
Takagi
H
H
D006084:Graft Rejection / Q000187:drug effects*; D006146:Guanidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation
D006146:Guanidines; D007166:Immunosuppressive Agents; C037258:gusperimus